BTIG analyst Mark Massaro maintained a Hold rating on OncoCyte (OCX – Research Report) on January 5. The company’s shares closed last Friday at $3.37.
According to TipRanks, Massaro is an analyst with an average return of -16.0% and a 30.80% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS.
OncoCyte has an analyst consensus of Moderate Buy, with a price target consensus of $3.30.
See the top stocks recommended by analysts >>
OCX market cap is currently $27.84M and has a P/E ratio of -0.26.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoCyte (OCX) Company Description:
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
Read More on OCX:
- Biotech Alert: Searches spiking for these stocks today
- Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
- OncoCyte begins FDA submissions process for VitaGraft transplant assays
- Oncocyte Reports Third Quarter 2023 Financial Results
- OncoCyte reports Q3 EPS (81c), consensus ($1.01)
